Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of “Buy” by Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has received a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $34.00.

A number of brokerages have recently issued reports on RCUS. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. HC Wainwright reaffirmed a “neutral” rating and issued a $20.00 price target on shares of Arcus Biosciences in a report on Wednesday, November 6th. Wells Fargo & Company started coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They set an “overweight” rating and a $29.00 target price for the company. Barclays upped their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research report on Thursday, October 3rd.

Insider Buying and Selling at Arcus Biosciences

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at $902,070. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 12.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Arcus Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the company. R Squared Ltd purchased a new stake in shares of Arcus Biosciences during the fourth quarter valued at $26,000. Point72 Hong Kong Ltd purchased a new stake in shares of Arcus Biosciences during the 3rd quarter valued at about $47,000. Point72 DIFC Ltd bought a new stake in shares of Arcus Biosciences in the second quarter worth approximately $83,000. Quest Partners LLC raised its holdings in shares of Arcus Biosciences by 40,904.3% during the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after purchasing an additional 9,408 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in Arcus Biosciences during the third quarter valued at approximately $244,000. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Price Performance

RCUS opened at $13.21 on Tuesday. Arcus Biosciences has a 1 year low of $12.88 and a 1 year high of $20.31. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The firm’s fifty day moving average price is $15.30 and its two-hundred day moving average price is $15.91. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -4.19 and a beta of 0.87.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.06. The company had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm’s revenue for the quarter was up 50.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.94) EPS. As a group, analysts anticipate that Arcus Biosciences will post -3.2 earnings per share for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.